Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch
Can Gamida Succeed On Its Own?
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
